Patent Struggles Could Determine Japanese iPS Cell Work
This article was originally published in PharmAsia News
The future of Japanese research and development of induced pluripotent stem cells could be determined by a possible patent competition. Bayer Yakuhin, the Japanese subsidiary of German's Bayer AG, says its researchers created iPS cells from human cells before a Kyoto University team, which announced its "breakthrough" work last November. In addition to Japanese researchers, the University of Wisconsin also has claimed success in creating iPS cells from human cells at the same time as the Kyoto University team. (Click here for more - a subscription may be required
You may also be interested in...
Chobani introduces Chobani Probiotic, its first functional probiotics beverage to support digestive and immune health; Danone North America extends its Danimals children’s yogurt line with products to support immune system; and Plexus Worldwide and Sofar Americas roll out children’s probiotics.
Report quantifies social media posts describing adverse events involving the Essure contraceptive device, which was pulled from the market amid safety concerns.
Deal Snapshot: The China/US CAR-T firm will be bought out by its management team and institutional investors in a deal structured as a merger into a new company.